The global Peripheral Intervention Drug-Eluting Devices market size was valued at US$ million in 2023. With growing demand in downstream market, the Peripheral Intervention Drug-Eluting Devices is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Peripheral Intervention Drug-Eluting Devices market. Peripheral Intervention Drug-Eluting Devices are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Peripheral Intervention Drug-Eluting Devices. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Peripheral Intervention Drug-Eluting Devices market.
Drug eluting devices are devices that are coated with anti-proliferated agent. These devices exert antirestenotic efficacy on the vessel wall to remove the blockade within the blood vessels caused by deposition of plaque.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Peripheral Intervention Drug-Eluting Devices market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Peripheral Intervention Drug-Eluting Devices market. It may include historical data, market segmentation by Type (e.g., Drug-Eluting Balloons, Drug-Eluting Stents), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Peripheral Intervention Drug-Eluting Devices market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Peripheral Intervention Drug-Eluting Devices market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Peripheral Intervention Drug-Eluting Devices industry. This include advancements in Peripheral Intervention Drug-Eluting Devices technology, Peripheral Intervention Drug-Eluting Devices new entrants, Peripheral Intervention Drug-Eluting Devices new investment, and other innovations that are shaping the future of Peripheral Intervention Drug-Eluting Devices.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Peripheral Intervention Drug-Eluting Devices market. It includes factors influencing customer ' purchasing decisions, preferences for Peripheral Intervention Drug-Eluting Devices product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Peripheral Intervention Drug-Eluting Devices market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Peripheral Intervention Drug-Eluting Devices market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Peripheral Intervention Drug-Eluting Devices market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Peripheral Intervention Drug-Eluting Devices industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Peripheral Intervention Drug-Eluting Devices market.
Market Segmentation:
Peripheral Intervention Drug-Eluting Devices market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Drug-Eluting Balloons
Drug-Eluting Stents
Segmentation by application
Plain Old Balloon Angioplasty (POBA)
Percutaneous Transluminal Angioplasty (PTA)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Medtronic plc
Boston Scientific Corporation
Abbott Laboratories
Cardinal Health
B. Braun Melsungen AG
Biosensors International Group Ltd.
C.R. Bard, Inc.
Abbott
The Lubrizol Corporation
Terumo Corporation
Key Questions Addressed in this Report
What is the 10-year outlook for the global Peripheral Intervention Drug-Eluting Devices market?
What factors are driving Peripheral Intervention Drug-Eluting Devices market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Peripheral Intervention Drug-Eluting Devices market opportunities vary by end market size?
How does Peripheral Intervention Drug-Eluting Devices break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peripheral Intervention Drug-Eluting Devices Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Peripheral Intervention Drug-Eluting Devices by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Peripheral Intervention Drug-Eluting Devices by Country/Region, 2019, 2023 & 2030
2.2 Peripheral Intervention Drug-Eluting Devices Segment by Type
2.2.1 Drug-Eluting Balloons
2.2.2 Drug-Eluting Stents
2.3 Peripheral Intervention Drug-Eluting Devices Sales by Type
2.3.1 Global Peripheral Intervention Drug-Eluting Devices Sales Market Share by Type (2019-2024)
2.3.2 Global Peripheral Intervention Drug-Eluting Devices Revenue and Market Share by Type (2019-2024)
2.3.3 Global Peripheral Intervention Drug-Eluting Devices Sale Price by Type (2019-2024)
2.4 Peripheral Intervention Drug-Eluting Devices Segment by Application
2.4.1 Plain Old Balloon Angioplasty (POBA)
2.4.2 Percutaneous Transluminal Angioplasty (PTA)
2.5 Peripheral Intervention Drug-Eluting Devices Sales by Application
2.5.1 Global Peripheral Intervention Drug-Eluting Devices Sale Market Share by Application (2019-2024)
2.5.2 Global Peripheral Intervention Drug-Eluting Devices Revenue and Market Share by Application (2019-2024)
2.5.3 Global Peripheral Intervention Drug-Eluting Devices Sale Price by Application (2019-2024)
3 Global Peripheral Intervention Drug-Eluting Devices by Company
3.1 Global Peripheral Intervention Drug-Eluting Devices Breakdown Data by Company
3.1.1 Global Peripheral Intervention Drug-Eluting Devices Annual Sales by Company (2019-2024)
3.1.2 Global Peripheral Intervention Drug-Eluting Devices Sales Market Share by Company (2019-2024)
3.2 Global Peripheral Intervention Drug-Eluting Devices Annual Revenue by Company (2019-2024)
3.2.1 Global Peripheral Intervention Drug-Eluting Devices Revenue by Company (2019-2024)
3.2.2 Global Peripheral Intervention Drug-Eluting Devices Revenue Market Share by Company (2019-2024)
3.3 Global Peripheral Intervention Drug-Eluting Devices Sale Price by Company
3.4 Key Manufacturers Peripheral Intervention Drug-Eluting Devices Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peripheral Intervention Drug-Eluting Devices Product Location Distribution
3.4.2 Players Peripheral Intervention Drug-Eluting Devices Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Peripheral Intervention Drug-Eluting Devices by Geographic Region
4.1 World Historic Peripheral Intervention Drug-Eluting Devices Market Size by Geographic Region (2019-2024)
4.1.1 Global Peripheral Intervention Drug-Eluting Devices Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Peripheral Intervention Drug-Eluting Devices Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Peripheral Intervention Drug-Eluting Devices Market Size by Country/Region (2019-2024)
4.2.1 Global Peripheral Intervention Drug-Eluting Devices Annual Sales by Country/Region (2019-2024)
4.2.2 Global Peripheral Intervention Drug-Eluting Devices Annual Revenue by Country/Region (2019-2024)
4.3 Americas Peripheral Intervention Drug-Eluting Devices Sales Growth
4.4 APAC Peripheral Intervention Drug-Eluting Devices Sales Growth
4.5 Europe Peripheral Intervention Drug-Eluting Devices Sales Growth
4.6 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Sales Growth
5 Americas
5.1 Americas Peripheral Intervention Drug-Eluting Devices Sales by Country
5.1.1 Americas Peripheral Intervention Drug-Eluting Devices Sales by Country (2019-2024)
5.1.2 Americas Peripheral Intervention Drug-Eluting Devices Revenue by Country (2019-2024)
5.2 Americas Peripheral Intervention Drug-Eluting Devices Sales by Type
5.3 Americas Peripheral Intervention Drug-Eluting Devices Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peripheral Intervention Drug-Eluting Devices Sales by Region
6.1.1 APAC Peripheral Intervention Drug-Eluting Devices Sales by Region (2019-2024)
6.1.2 APAC Peripheral Intervention Drug-Eluting Devices Revenue by Region (2019-2024)
6.2 APAC Peripheral Intervention Drug-Eluting Devices Sales by Type
6.3 APAC Peripheral Intervention Drug-Eluting Devices Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Peripheral Intervention Drug-Eluting Devices by Country
7.1.1 Europe Peripheral Intervention Drug-Eluting Devices Sales by Country (2019-2024)
7.1.2 Europe Peripheral Intervention Drug-Eluting Devices Revenue by Country (2019-2024)
7.2 Europe Peripheral Intervention Drug-Eluting Devices Sales by Type
7.3 Europe Peripheral Intervention Drug-Eluting Devices Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peripheral Intervention Drug-Eluting Devices by Country
8.1.1 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Sales by Country (2019-2024)
8.1.2 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Revenue by Country (2019-2024)
8.2 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Sales by Type
8.3 Middle East & Africa Peripheral Intervention Drug-Eluting Devices Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peripheral Intervention Drug-Eluting Devices
10.3 Manufacturing Process Analysis of Peripheral Intervention Drug-Eluting Devices
10.4 Industry Chain Structure of Peripheral Intervention Drug-Eluting Devices
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peripheral Intervention Drug-Eluting Devices Distributors
11.3 Peripheral Intervention Drug-Eluting Devices Customer
12 World Forecast Review for Peripheral Intervention Drug-Eluting Devices by Geographic Region
12.1 Global Peripheral Intervention Drug-Eluting Devices Market Size Forecast by Region
12.1.1 Global Peripheral Intervention Drug-Eluting Devices Forecast by Region (2025-2030)
12.1.2 Global Peripheral Intervention Drug-Eluting Devices Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Peripheral Intervention Drug-Eluting Devices Forecast by Type
12.7 Global Peripheral Intervention Drug-Eluting Devices Forecast by Application
13 Key Players Analysis
13.1 Medtronic plc
13.1.1 Medtronic plc Company Information
13.1.2 Medtronic plc Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.1.3 Medtronic plc Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Medtronic plc Main Business Overview
13.1.5 Medtronic plc Latest Developments
13.2 Boston Scientific Corporation
13.2.1 Boston Scientific Corporation Company Information
13.2.2 Boston Scientific Corporation Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.2.3 Boston Scientific Corporation Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Boston Scientific Corporation Main Business Overview
13.2.5 Boston Scientific Corporation Latest Developments
13.3 Abbott Laboratories
13.3.1 Abbott Laboratories Company Information
13.3.2 Abbott Laboratories Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.3.3 Abbott Laboratories Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Abbott Laboratories Main Business Overview
13.3.5 Abbott Laboratories Latest Developments
13.4 Cardinal Health
13.4.1 Cardinal Health Company Information
13.4.2 Cardinal Health Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.4.3 Cardinal Health Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Cardinal Health Main Business Overview
13.4.5 Cardinal Health Latest Developments
13.5 B. Braun Melsungen AG
13.5.1 B. Braun Melsungen AG Company Information
13.5.2 B. Braun Melsungen AG Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.5.3 B. Braun Melsungen AG Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 B. Braun Melsungen AG Main Business Overview
13.5.5 B. Braun Melsungen AG Latest Developments
13.6 Biosensors International Group Ltd.
13.6.1 Biosensors International Group Ltd. Company Information
13.6.2 Biosensors International Group Ltd. Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.6.3 Biosensors International Group Ltd. Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Biosensors International Group Ltd. Main Business Overview
13.6.5 Biosensors International Group Ltd. Latest Developments
13.7 C.R. Bard, Inc.
13.7.1 C.R. Bard, Inc. Company Information
13.7.2 C.R. Bard, Inc. Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.7.3 C.R. Bard, Inc. Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 C.R. Bard, Inc. Main Business Overview
13.7.5 C.R. Bard, Inc. Latest Developments
13.8 Abbott
13.8.1 Abbott Company Information
13.8.2 Abbott Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.8.3 Abbott Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Abbott Main Business Overview
13.8.5 Abbott Latest Developments
13.9 The Lubrizol Corporation
13.9.1 The Lubrizol Corporation Company Information
13.9.2 The Lubrizol Corporation Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.9.3 The Lubrizol Corporation Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 The Lubrizol Corporation Main Business Overview
13.9.5 The Lubrizol Corporation Latest Developments
13.10 Terumo Corporation
13.10.1 Terumo Corporation Company Information
13.10.2 Terumo Corporation Peripheral Intervention Drug-Eluting Devices Product Portfolios and Specifications
13.10.3 Terumo Corporation Peripheral Intervention Drug-Eluting Devices Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Terumo Corporation Main Business Overview
13.10.5 Terumo Corporation Latest Developments
14 Research Findings and Conclusion
*If Applicable.